绿叶制药(02186.HK)创新药赞必佳获得国家药监局上市批准

阿斯达克财经
03 Dec 2024

绿叶制药(02186.HK) 公布,其创新药赞必佳(注射用芦比替定)作为被纳入优先审评审批程序的品种,已获得中国国家药品监督管理局的上市批准,适用于治疗含铂化疗中或化疗后疾病进展的转移性小细胞肺癌(SCLC)成人患者。

截至目前,赞必佳共在全球17个国家或地区获得上市批准。集团获权在内地、香港、澳门地区开发和商业化该产品,并已成功推动其在上述三地获批上市。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-03 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10